Zydus Wellness is in the limelight today morning, rising 6.5% the moment is opened for trade at Rs.2249.90 and is now trading at Rs.2157 levels.
Two reasons- firstly, the company is expected to announce its performance today. Secondly, India’s second indigenously-developed vaccine, ZyCoV-D, made by Zydus Cadilla is nearing completion of its advanced Phase-III clinical trials on 30,000 volunteers and will soon submit findings to the drug regulator for review.
The vaccine was found to be safe, well-tolerated and immunogenic in the Phase I/II clinical trials conducted in 2020.
The company is optimistic that its three-dose plasmid DNA vaccine, ZyCoV-D, will offer sustained immunity with longer antibody response.
Unlike most vaccines, which use a needle to inject the vaccine into the tissue, ZyCov-D will be administered without a needle, but using intra-dermal injection that will push the substance into the dermis.